Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06161844
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2023-11-30
Brief Title:
Efficacy and Safety of Semaglutide Injection HD1916 in Patients with Type 2 Diabetes Mellitus
Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Organization:
CSPC ZhongQi Pharmaceutical Technology Co Ltd
Study Overview
Official Title:
A Phase 3 Randomized Open-label Parallel-group Multicenter Controlled Study to Evaluate Efficacy and Safety of Semaglutide Injection HD1916 Vs Ozempic As Add-on to Metformin in Patients with Type 2 Diabetics Mellitus
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the similarity of the efficacy and safety of semaglutide injection HD1916 vs Ozempic in patients with type 2 diabetes mellitus T2DM with poor blood glucose control after metformin treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None